Sudeep Pharma Ltd Q2 FY2027 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/45kfp6dbqt9kvggz2dc9i6ps.pdf

Key Takeaways


PFN: The Core Growth Engine

Shanil Bhayani: "With growing customer interest, progress in approvals and additional capacity becoming available, we are optimistic that magnesium bisglycinate can become one of the top 3 revenue contributors within PFN over the next 2 to 3 years."

Specialty Ingredients: The Drag, With a Promised H2 Rebound

Shanil Bhayani: "Importantly, this expectation is based on customer contracts and new business alone and does not assume a restart of the Fortified Rice program."

Greenfield Facility: FDA Approval Unlocks the Pipeline


Battery Materials: The Big Bet, De-Risked in Stages

Shanil Bhayani: "We are the first and only company today to produce at scale battery grade iron phosphate. We have an indigenous tech, which is proprietary. It is green chemistry, is very competitive on opex, has very good -- and also it is delivering at par product performance."
Shanil Bhayani: "Our goal is not to compete with China. We have positioned Sudeep as an ex-China source which operates at a slight premium. The premium cannot be 100% because you still have to be competitive and the end customer has to be competitive. But it would be -- it would largely be at a price higher than China."

Financial Health: Margins, Returns and the Working Capital Overhang


Guidance & Commitments

CommitmentSpecificsTimeline
Specialty Ingredients revenue recoveryReturn to positive YoY growth, based on customer contracts and new business alone, without assuming Fortified Rice program restartQ3 and Q4 FY27
Specialty Ingredients margin recoveryMargins to improve back to pre-Q2 levels or levels of the last couple of financial yearsQ3 and Q4 FY27
Greenfield PFN commercial suppliesSmall quantities to begin, with larger flow thereafterQ3 FY27 (small), Q4 FY27 (larger)
Greenfield PFN utilization ramp15-20% utilization targetFY28
Greenfield PFN full ramp75% optimum utilization with close to 3x asset turnover3- to 4-year period
Magnesium bisglycinate revenueAt least ₹100 cr, becoming a top-3 PFN revenue contributor2-3 years
Battery materials binding offtake updateConcrete update on firm binding contracts, broken out by customer and offtakes up to and beyond 100 KTPAQ4 FY27
Battery materials commercial operationsCommence commercial operationsApril 2027
Battery materials Phase 1 revenueCommercial supplies and revenue generation begin, assuming ~6 months for customer site validation post-commissioningH2 FY28
Battery materials Phase 2/3 decisionGated by delivery visibility from binding commitmentsPost binding commitments
NSS performanceFlattish year; growth at a similar pace to core business growth; target EBITDA margin close to 30%, barring supply-side shocksFY27 (flattish), FY28 (growth)
Working capital reduction170-180 days, excluding battery materials inventoryFY27
Working capital long-term target~150 daysLonger period

Key Metrics

MetricQ2 FY27
Revenue from operations₹196.7 cr, +21% YoY and +24% QoQ
EBITDA₹73.2 cr, +32% YoY and +33% QoQ
EBITDA margin37.2%, +310 bps YoY (34.1% in Q2 FY26)
Gross margin64.7%, vs 62.5% in Q2 FY26
PAT₹51.8 cr, +11% YoY
PAT margin26.3%
Effective tax rate27%, vs ~21% in Q2 FY26
Other incomelower by ₹6 cr vs ₹10.2 cr in Q2 FY26
Pharma Food Nutrition revenue₹142 cr, +57% YoY, ~72% of consolidated revenue
PFN segment EBITDA margin~41%, vs 33% in Q2 FY26; segment EBITDA nearly doubled
Specialty Ingredients revenue₹54 cr, +9% QoQ, -25% YoY
Export share~65% of revenue; exports grew 24% YoY
Net working capital days214 days as of 30 Sep 2026, similar to March 2026
Net debt₹72.5 cr, net debt-to-equity 0.07x (vs ₹33.6 cr and 0.04x as of 31 Mar 2026)
Annualized ROCE (H1 FY27)22.4%
Annualized ROE (H1 FY27)19%
Capex in FY27~₹77 cr, mainly towards Battery Materials and greenfield facility completion
Cash flow from operations (H1 FY27)₹43.5 cr, up ₹26 cr YoY
Selling & distribution expenditure~₹8 cr above normal quarterly average, largely because of freight
Greenfield facility capacity (Nandesari)51,000 tons annual capacity; FDA approval received during the quarter; customer qualifications underway, commercial supplies expected H2 FY27
Magnesium bisglycinate average realization>3x the average of PFN portfolio
Battery Materials Phase 1 capacity25,000 tons of battery-grade iron phosphate; commercial operations expected April 2027